Technical Innovations and Patient Support in Radiation Oncology最新文献

{"title":"Radiation therapist research capacity and output: a multicentre retrospective study of authorship, collaboration, and institutional strategies (2013–2022)","authors":"Caroline Marr ,&nbsp;Tara Rosewall ,&nbsp;Helen A McNair ,&nbsp;Maddalena M.G. Rossi ,&nbsp;Yat Tsang","doi":"10.1016/j.tipsro.2025.100351","DOIUrl":"10.1016/j.tipsro.2025.100351","url":null,"abstract":"<div><h3>Purpose</h3><div>Radiation Therapist (RTT) research culture is essential for driving innovation and informing evidence-based practice. This study aimed to assess RTT research output and institutional capacity-building initiatives across international clinical academic cancer centres.</div></div><div><h3>Methods</h3><div>This was a retrospective analysis of RTT research activities and capacity-building initiatives from 2013 to 2022 at three centres located in Canada (CA), the Netherlands (NL) and the United Kingdom (UK). Data was collected on research output by identifying all RTT author publications (first, second, or senior author). Institutional capacity-building initiatives were captured from each centre and described using full-time equivalents (FTEs). A qualitative analysis was conducted on all RTT<!--> <!-->publications to identify common research topics.</div></div><div><h3>Results</h3><div>Over the 10 years, the total number of RTT-authored publications was 445 across the centres (CA:291; UK:79; NL:75). RTTs as first authors ranged from 14.7 % to 44.3 % and RTTs as senior authors ranged from 0 % to 27.8 % of publications. Centres with increasing FTEs demonstrated increasing research productivity, with publications changing from 21 to 34 in CA and from 3 to 15 in the UK centre. Multidisciplinary collaboration was common among all centres. Prominent RTT research themes included technological applications, RTT professional development and quality assurance, clinical outcomes, dosimetry, and patient care. Common strategies to build research capacity included educational initiatives, the creation of dedicated research roles, and promoting research dissemination.</div></div><div><h3>Conclusion</h3><div>This study highlighted the contributions of RTTs to radiation oncology research and how a comprehensive approach to building research capacity results in high RTT research output and collaboration.</div></div>","PeriodicalId":36328,"journal":{"name":"Technical Innovations and Patient Support in Radiation Oncology","volume":"36 ","pages":"Article 100351"},"PeriodicalIF":2.8,"publicationDate":"2025-10-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145466084","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Monitoring lung tumour volume on daily cone beam CT; is it achievable in a real-world setting?","authors":"Sarah Barrett ,&nbsp;Laure Marignol ,&nbsp;Gerard G Hanna ,&nbsp;Conor K McGarry ,&nbsp;Gerard M Walls","doi":"10.1016/j.tipsro.2025.100352","DOIUrl":"10.1016/j.tipsro.2025.100352","url":null,"abstract":"<div><div>Delineating the gross tumour volume (GTV) in non-small cell lung cancer (NSCLC) can be challenging due to anatomical complexities and imaging artefacts. This study evaluates a semi-automated workflow using commercial software for target volume (TV) delineation on cone-beam CT (CBCT) in patients undergoing radical radiotherapy. Seventy-six patients with 553 scans (n = 76 planning CT, n = 477 CBCT) were included. Auto-contours were adjusted by a senior Radiation Therapist and reviewed for accuracy. The majority (59.1 %) required only minor revisions, with median adjustment time of CBCT auto-contours of 83 (range 0–460) seconds. The findings support the feasibility of this approach, offering a pragmatic solution for adaptive radiotherapy workflows in NSCLC.</div></div>","PeriodicalId":36328,"journal":{"name":"Technical Innovations and Patient Support in Radiation Oncology","volume":"36 ","pages":"Article 100352"},"PeriodicalIF":2.8,"publicationDate":"2025-10-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145417199","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Advancing proton therapy together: insights on practice, technology, and implementation","authors":"Taeyoon Kim,&nbsp;Nicola Bizzocchi","doi":"10.1016/j.tipsro.2025.100350","DOIUrl":"10.1016/j.tipsro.2025.100350","url":null,"abstract":"","PeriodicalId":36328,"journal":{"name":"Technical Innovations and Patient Support in Radiation Oncology","volume":"36 ","pages":"Article 100350"},"PeriodicalIF":2.8,"publicationDate":"2025-10-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145466083","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Operational assessment of tattooless breast radiotherapy using AlignRT surface guidance","authors":"Aria Malhotra ,&nbsp;Andrew K.H. Robertson ,&nbsp;Ian Sun ,&nbsp;Samantha A.M. Lloyd","doi":"10.1016/j.tipsro.2025.100349","DOIUrl":"10.1016/j.tipsro.2025.100349","url":null,"abstract":"<div><h3>Background and purpose</h3><div>Surface guided radiation therapy (SGRT) is a new approach for patient setup that can replace tattoo-based positioning. The permanent body markings that come with this long-standing standard of care can have a lasting negative emotional impact on cancer survivors. This study evaluates surface guidance as an alternative positioning modality, comparing speed, accuracy, and cost of the two techniques.</div></div><div><h3>Methods</h3><div>Setup time and positional accuracy prior to radiographic localization for patients receiving radiation therapy for breast cancer were compared between two linear accelerators, one with and one without surface guidance technology. A Wilcoxon rank sum test was used to determine statistically significant differences in setup time and positional shifts. Cost projections per fraction and per patient for both modalities were conducted.</div></div><div><h3>Results</h3><div>SGRT positional accuracy and setup time were equivalent to or better than tattoo-based setup. SGRT setup was faster for all photon treatments by 11 s. Deep inspiration breath hold setup times were equivalent for both positioning modalities, but SGRT was faster by 23 s for free breathing setups. There were no statistically significant differences in the magnitude of positional shifts on pre-treatment imaging. SGRT costs are broken down into item costs and staffing costs, with final estimates dependent on a center’s capacity for treatments per day.</div></div><div><h3>Conclusions</h3><div>Surface guided patient positioning for breast radiotherapy is fiscally feasible and non-inferior to permanent tattoos in terms of set up time and accuracy.</div></div>","PeriodicalId":36328,"journal":{"name":"Technical Innovations and Patient Support in Radiation Oncology","volume":"36 ","pages":"Article 100349"},"PeriodicalIF":2.8,"publicationDate":"2025-10-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145362465","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Three-year insights from a proton therapy centre: Evolving strategies in ependymoma treatment planning","authors":"Lieselotte Lauwens ,&nbsp;Anneleen Goedgebeur ,&nbsp;Tom Boterberg ,&nbsp;Tom Depuydt ,&nbsp;Dario Di Perri ,&nbsp;Lorraine Donnay ,&nbsp;Benjamin Ledoux ,&nbsp;Kenneth Poels ,&nbsp;Susana Santos Lopes ,&nbsp;Karen Van Beek ,&nbsp;Robin De Roover ,&nbsp;Maarten Lambrecht","doi":"10.1016/j.tipsro.2025.100347","DOIUrl":"10.1016/j.tipsro.2025.100347","url":null,"abstract":"<div><h3>Background</h3><div>Treatment of posterior fossa ependymoma with proton therapy (PT) is challenging due to the proximity to the brainstem and potential risk of brainstem toxicity.</div></div><div><h3>Materials and methods</h3><div>This retrospective study included patients with intracranial ependymoma treated with PT or a hybrid proton–photon (PT-XT) approach at our centre between July 2020 and December 2023 with a minimum 12 month follow-up. Treatment approach was determined based on tumour relationship to the brainstem. Patient and tumour characteristics and treatment planning approaches were evaluated, and dosimetric data between PT and PT-XT approaches were compared. Outcomes including symptomatic brainstem injury (SBI) and asymptomatic radiographic changes (ARC) were assessed.</div></div><div><h3>Results</h3><div>Fourteen patients were included, of which nine had posterior fossa ependymoma, with five treated using a hybrid PT-XT planning approach and four with PT alone. The hybrid PT-XT approach involved delivering 75 % of the treatment (0–45 Gy(RBE)) with PT and the remaining portion (45–59.4 Gy) with XT, addressing concerns regarding increased relative biological effectiveness of PT in the brainstem. While all plans adhered to the European Particle Therapy Network D_0.03cc brainstem dose constraint, the University of Florida constraints were not always met. Comparison of the hybrid PT-XT and PT-only replans showed a trend towards improved brainstem dose parameters with the hybrid approach. After a median follow-up of 22.2 months, no patients developed symptomatic brainstem injury and three showed asymptomatic radiographic changes.</div></div><div><h3>Conclusion</h3><div>Tailored planning approaches, depending on location and relationship to the brainstem, are essential when treating ependymoma patients. A hybrid PT-XT approach, is feasible in well-selected patients, demonstrating acceptable target coverage, brainstem doses, and to date no occurrence of symptomatic brainstem injury.</div></div>","PeriodicalId":36328,"journal":{"name":"Technical Innovations and Patient Support in Radiation Oncology","volume":"36 ","pages":"Article 100347"},"PeriodicalIF":2.8,"publicationDate":"2025-10-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145321263","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Evaluating participant experiences and tolerability with MR Linac imaging","authors":"Jayde Nartey ,&nbsp;Helen A. McNair ,&nbsp;Katie Biscombe ,&nbsp;Sophie E. Alexander ,&nbsp;Charlotte Cherry ,&nbsp;Cynthia Eccles ,&nbsp;Trina Herbert ,&nbsp;Shaista Hafeez ,&nbsp;Kelly Jones ,&nbsp;Francesca Mason ,&nbsp;Simeon Nill ,&nbsp;Hosna Mohammad ,&nbsp;Kian Morrison ,&nbsp;Bethany Williams ,&nbsp;Robert Huddart","doi":"10.1016/j.tipsro.2025.100348","DOIUrl":"10.1016/j.tipsro.2025.100348","url":null,"abstract":"<div><h3>Introduction</h3><div>Magnetic Resonance Image Guided Radiotherapy (MRIgRT) integrates MRI with a linear accelerator to enable adaptive treatment delivery. While technical feasibility is well established, patient experience during MR Linac imaging, especially outside treatment sessions, remains underexplored. This study evaluates tolerability, pre-scan anxiety, coping ability, willingness for future scans, and scan-induced symptoms in patients and non-patient volunteers.</div></div><div><h3>Materials and Methods</h3><div>Participants who successfully underwent MR Linac imaging between November 2017 and December 2023 completed a bespoke MR Linac Participant Experience Questionnaire, developed by the PRIMER study team and informed by MRI patient experience literature. The questionnaire assessed pre-scan anxiety, coping, willingness for future scans, and scan-related symptoms using Likert-scale responses. Descriptive analyses summarised responses by participant group and anatomical site.</div></div><div><h3>Results</h3><div>In total, 447 participants (319 patients; 128 non-patient volunteers) completed MR Linac imaging and the questionnaire. Overall tolerability was high, with 65 % strongly disagreeing they felt anxious prior to scanning and most participants reporting good coping ability. Variability was observed across anatomical sites: Participants undergoing head and neck, brain, and oligometastatic bone scans reported higher pre-scan anxiety, with coping difficulties most frequently reported by the head and neck group. Non-patient volunteers reported more physiological symptoms (e.g., sweating, nausea, dizziness) than patients, whereas patients undergoing head and neck and bone oligometastases scans were more reluctant to repeat the procedure. Most patients perceived MR Linac imaging as easier or comparable to diagnostic MRI, though 20 % of brain cancer patients found it more difficult.</div></div><div><h3>Conclusion</h3><div>MR Linac imaging is generally well tolerated, though specific subgroups, particularly those requiring immobilisation, report greater anxiety and discomfort. These findings highlight the need for tailored strategies to improve patient experience, supporting wider implementation of MRIgRT.</div></div>","PeriodicalId":36328,"journal":{"name":"Technical Innovations and Patient Support in Radiation Oncology","volume":"36 ","pages":"Article 100348"},"PeriodicalIF":2.8,"publicationDate":"2025-10-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145269092","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Incidental dose to internal mammary nodes in post-operative radiation therapy for breast cancer","authors":"L.Di Lena ,&nbsp;A.W.M. Nielsen ,&nbsp;C.P.L. Fulcheri ,&nbsp;M. Marcantonini ,&nbsp;I. Palumbo ,&nbsp;S. Saldi ,&nbsp;V. Bini ,&nbsp;B.V. Offersen ,&nbsp;C. Aristei","doi":"10.1016/j.tipsro.2025.100346","DOIUrl":"10.1016/j.tipsro.2025.100346","url":null,"abstract":"<div><h3>Aims</h3><div>The incidental dose to the internal mammary nodes (IMN) is understudied in patients treated with newer radiation therapy (RT) techniques. The aim of this study was to quantify the incidental IMN dose in a series of breast cancer (BC) patients receiving post-operative RT to the chest wall/breast and regional nodes (level III-IV).</div></div><div><h3>Methods</h3><div>We retrospectively analyzed data from 95 high-risk BC patients treated between 2015 and 2022. Patients received RT (50 Gy/25fr or 40.05 Gy/15fr) to the breast/chest wall and nodal levels III-IV after mastectomy or breast conserving surgery (BCS). Exclusion criteria were IMN irradiation and pre-operative systemic therapy. One radiation oncologist contoured the CTV_IMN according to ESTRO guidelines and divided it into four sub-regions based on intercostal spaces (ICS): IMNupper, ICS1, ICS2, ICS3. Dosimetric parameters collected were Dmean, V90, V95, D90, and D95. The Dmean was correlated to tumor laterality and location, type of surgery and reconstruction, RT technique (3D-CRT, IMRT, helical RT) and boost.</div></div><div><h3>Results</h3><div>Mean Dmean to IMN was 71.4 % (range 19.6–118.6) of the prescription dose. Among sub-region, ICS2 and ICS3 received significantly higher doses than ICS1 and IMN upper (p = 0.04). V90 of over 90 % was achieved in only 4/95 patients, 3 were treated with helical RT, and the other with IMRT. The mean V95 and V90 were 15.4 % and 26.2 % respectively. Univariate analysis showed that mastectomy (p = 0.002), omission of boost (p = 0.001), and helical RT (p &lt; 0.0001) were associated with significantly higher IMN Dmean. No significant correlation emerged with laterality, tumor location and type of reconstruction.</div></div><div><h3>Conclusions</h3><div>In our series, incidental IMN doses were highest after mastectomy and with helical RT delivery, possibly due to more medial margin in chest wall delineation and the helical dose distribution. Nevertheless, incidental doses to the IMN were below recommended doses, thus highlighting the need for IMN contouring when identified as targets.</div></div>","PeriodicalId":36328,"journal":{"name":"Technical Innovations and Patient Support in Radiation Oncology","volume":"36 ","pages":"Article 100346"},"PeriodicalIF":2.8,"publicationDate":"2025-09-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145221916","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A prospective audit of thoracic reirradiation practice and peer-review in a high-volume academic center","authors":"Geraldine Murphy ,&nbsp;Daniel Tong ,&nbsp;Grace Wu ,&nbsp;B.C. John Cho ,&nbsp;Meredith Giuliani ,&nbsp;Andrew Hope ,&nbsp;Benjamin H. Lok ,&nbsp;Alexander Sun ,&nbsp;Jean-Pierre Bissonnette ,&nbsp;Andrea Bezjak","doi":"10.1016/j.tipsro.2025.100345","DOIUrl":"10.1016/j.tipsro.2025.100345","url":null,"abstract":"<div><h3>Background</h3><div>Reirradiation is an increasingly common challenge with limited prospective evidence to guide practice, which varies internationally. This paper presents the patterns of practice in thoracic reirradiation within a high-volume academic center.</div></div><div><h3>Methods</h3><div>Thoracic reirradiation cases, discussed at the thoracic radiotherapy quality assurance (QA) meeting, were prospectively collected over 12 months between April 2024 and March 2025. Data collected included patient demographics, primary tumor site, details of previous and current planned radiotherapy, the extent and type of overlap and any treatment plan modifications. The data was analyzed using descriptive statistics.</div></div><div><h3>Results</h3><div>85 (18.2 % of 466 cases) reirradiation cases were identified at 26 QA meetings. Most reirradiation plans (68.2 %) were of radical intent, with dose overlap (89.4 %, n = 76). Challenges included unreliable registration of prior radiotherapy datasets (16.5 %) and deciding appropriate plan modifications to improve safety: 24.7 % optimized dose distribution to an OAR, 23.5 % involved dose reductions from standard prescriptions and 15.3 % compromised target volume coverage. The most frequently identified dose-limiting OARs were the proximal bronchial tree, esophagus, and spinal cord. Concerns about a lack of normal tissue recovery arose in 7.1 % of cases. In 10.6 % of cases there was explicit discussion of a dose discount for OARs for presumed partial tissue recovery. Peer-review prompted revision of the treatment plan in 11.8 % of cases.</div></div><div><h3>Conclusion</h3><div>These findings underscore the complexity of thoracic reirradiation and highlight the need for further guidance in the area and the role of QA rounds in optimizing safety and treatment decisions while best practice remains uncertain.</div></div>","PeriodicalId":36328,"journal":{"name":"Technical Innovations and Patient Support in Radiation Oncology","volume":"36 ","pages":"Article 100345"},"PeriodicalIF":2.8,"publicationDate":"2025-09-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145269093","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Patient perspectives on participation in the Danish Breast Cancer Group Proton Trial: A qualitative research study","authors":"Kristine W. Høgsbjerg ,&nbsp;Anne W. Kristensen ,&nbsp;Mette Møller ,&nbsp;Else Maae ,&nbsp;Maja V. Maraldo ,&nbsp;Louise W. Matthiessen ,&nbsp;Sami Al-Rawi ,&nbsp;Mette H. Nielsen ,&nbsp;Cai Grau ,&nbsp;Birgitte V. Offersen","doi":"10.1016/j.tipsro.2025.100344","DOIUrl":"10.1016/j.tipsro.2025.100344","url":null,"abstract":"<div><h3>Background and purpose</h3><div>Participation in clinical trials is essential to advancing oncological treatments, yet equitable trial access remains challenging. Diverse patient inclusion strengthens external validity and enhances the generalisability of trial outcomes. However, barriers to trial participation persist, and the factors influencing patient enrolment are not fully understood. This study investigates the patient perspective on participation in the Danish Breast Cancer Group (DBCG) Proton Trial.</div></div><div><h3>Materials and methods</h3><div>Patients eligible for the DBCG Proton Trial were invited to participate in interviews. Patients were selected to ensure geographical and perspective-based diversity, including randomised and non-randomised patients from eight radiotherapy clinics in Denmark. Semi-structured interviews were conducted via telephone, transcribed, and analysed using an inductive approach to identify the patient perspective on trial participation.</div></div><div><h3>Results</h3><div>A total of fifteen patients were interviewed. The analysis identified five themes encompassing patients’ motivators and barriers to trial participation: distance to the treatment facility, timing of trial information, decisional support, clinical equipoise and patient needs. These factors were reported by both randomised and non-randomised patients.</div></div><div><h3>Interpretation</h3><div>Participation in the DBCG Proton Trial was determined by both logistical and personal factors. Distance to the proton treatment facility was the most important barrier, while the potential for reduced late effects was the main motivator. The decision was difficult for most patients, often guided by one dominant concern rather than a balanced consideration of multiple factors. These findings suggest that improved trial communication, decisional support, and attention to geographical barriers are essential for promoting equitable participation in clinical trials.</div></div>","PeriodicalId":36328,"journal":{"name":"Technical Innovations and Patient Support in Radiation Oncology","volume":"36 ","pages":"Article 100344"},"PeriodicalIF":2.8,"publicationDate":"2025-09-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145100117","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Beyond the first course: Re-irradiation practices in Ontario — Insights from a provincial survey","authors":"Brian Liszewski ,&nbsp;Timothy P Hanna ,&nbsp;Nareesa Ishmail ,&nbsp;Kyle Malkoske ,&nbsp;Laura D’Alimonte ,&nbsp;Jason Pantarotto ,&nbsp;Eric Gutierrez ,&nbsp;Julie Kraus ,&nbsp;Angelica Ramprashad ,&nbsp;Kristin Berry","doi":"10.1016/j.tipsro.2025.100343","DOIUrl":"10.1016/j.tipsro.2025.100343","url":null,"abstract":"<div><div>Re-irradiation is an increasingly important aspect of cancer care, as more patients undergo more complex, multi-course radiation therapy, often across multiple cancer centres. To better understand how re-irradiation is planned and delivered, Ontario Health (Cancer Care Ontario)’s Radiation Treatment Program conducted a provincial review using administrative data and a structured survey of all 15 Regional Cancer Centres (RCC) that provide all radiation therapy to Ontario’s 16 million people. The findings offered insight into current practices, including institutional policies, clinical workflows, technical planning methods, and interprofessional collaboration. As the complexity of care continues to grow, there is a clear need to harmonize these elements across institutions to support the safe, effective, and consistent delivery of re-irradiation. These findings are helping inform system-wide efforts to strengthen coordination and improve quality across the RCCs within Ontario.</div></div>","PeriodicalId":36328,"journal":{"name":"Technical Innovations and Patient Support in Radiation Oncology","volume":"36 ","pages":"Article 100343"},"PeriodicalIF":2.8,"publicationDate":"2025-09-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145047860","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}